Where can I buy shares of ettx?
Shares of ETTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
What was the earnings report for Entasis Therapeutics Holdings (ettx)?
Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) issued its quarterly earnings data on Thursday, November, 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.26). During the same period last year, the business earned ($0.37) earnings per share.
What happened with the ETX IPO?
(ETTX) raised $75 million in an initial public offering on Wednesday, September 26th 2018. The company issued 4,400,000 shares at $16.00-$18.00 per share. Credit Suisse and BMO Capital Markets served as the underwriters for the IPO and SunTrust Robinson Humphrey and Wedbush PacGrow were co-managers.
Is ETTX stock a buy right now?
5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Entasis Therapeutics in the last twelve months. There are current...
Will Entasis Therapeutics' stock price go up in 2022?
5 analysts have issued 1-year target prices for Entasis Therapeutics' shares. Their forecasts range from $1.80 to $7.00. On average, they predict E...
How has Entasis Therapeutics' stock price performed in 2022?
Entasis Therapeutics' stock was trading at $2.19 on January 1st, 2022. Since then, ETTX shares have increased by 0.0% and is now trading at $2.19....
Are investors shorting Entasis Therapeutics?
Entasis Therapeutics saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 105,100 shares, a decli...
When is Entasis Therapeutics' next earnings date?
Entasis Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022. View our earnings forecast f...
How were Entasis Therapeutics' earnings last quarter?
Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) announced its earnings results on Wednesday, April, 27th. The company reported ($0.32) EPS for the...
Who are Entasis Therapeutics' key executives?
Entasis Therapeutics' management team includes the following people: Dr. Manoussos Perros Ph.D. , Pres, CEO & Director (Age 54, Pay $1.09M) ( Li...
Who are some of Entasis Therapeutics' key competitors?
Some companies that are related to Entasis Therapeutics include COMPASS Pathways (CMPS) , Albireo Pharma (ALBO) , Arbutus Biopharma (ABUS) , Ki...
What other stocks do shareholders of Entasis Therapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Entasis Therapeutics investors own include VBI Vaccines (V...
Is Entasis Therapeutics Holdings stock a Buy, Sell or Hold?
Entasis Therapeutics Holdings stock hasn't recieved a clear consensus rating. The average rating score is and is based on 3 buy ratings, 3 hold rat...
What was the 52-week low for Entasis Therapeutics Holdings stock?
The low in the last 52 weeks of Entasis Therapeutics Holdings stock was 1.40. According to the current price, Entasis Therapeutics Holdings is 155....
What was the 52-week high for Entasis Therapeutics Holdings stock?
The high in the last 52 weeks of Entasis Therapeutics Holdings stock was 3.86. According to the current price, Entasis Therapeutics Holdings is 56....
What are analysts forecasts for Entasis Therapeutics Holdings stock?
The 6 analysts offering price forecasts for Entasis Therapeutics Holdings have a median target of 4.60, with a high estimate of 9.00 and a low esti...
About Entasis Therapeutics
Entasis Therapeutics (NASDAQ:ETTX) Frequently Asked Questions
Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections.
What time do you trade in the pre market?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Entasis Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Entasis Therapeutics stock. View analyst ratings for Entasis Therapeutics or view top-rated stocks.
Does market cap include convertible securities?
Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these sessions may offer less liquidity and inferior prices. Stock prices may also move more quickly in this environment.
Premium Research for ETTX
It does not include securities convertible into the common equity securities. "Market Cap" is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities (as applicable).
Company Summary
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.